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Purpose: To investigate visual and morphological outcome in eyes with MRS and
choroidal neovascularization (CNV) secondary to pathologic myopia treated with intravitreal
(IVT) ranibizumab.
Methods: Post hoc analysis of the patients included in the RADIANCE trial (n = 277) was
performed to evaluate the impact of MRS on the functional outcome in patients with myopic
choroidal neovascularization (mCNV) undergoing intravitreal ranibizumab injections.
Results: Prevalence of MRS in pathologic myopia population is 6%. Respective patients
were generally older than patients without MRS. Study eyes with MRS at baseline (BL)
showed an initially poor treatment response after 3 months (mean change in best corrected
visual acuity (BCVA) was 2.8 ± 12.4 letters, P = 0.009). After 12 months of treatment
however, the mean change in BCVA was 7.1 ± 14.5 early treatment diabetic retinopathy
study (ETDRS) letters (P = 0.025). Patients with MRS at baseline received more intravitreal
injections than the other RADIANCE patients without MRS (MRS, n = 15 eyes: 5.8 ± 2.1 vs.
RADIANCE non-MRS [n = 207 eyes]: 4.0 ± 2.9; P = 0.0001).
Conclusion: Improvement of visual acuity is delayed and reduced after 3 months
intravitreal ranibizumab in eyes with MRS and myopic choroidal neovascularization
compared to eyes without MRS. More ranibizumab injections are needed in eyes with
MRS to gain comparable BCVA at Month 12.
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Myopia is one of the leading causes of visualimpairment worldwide.1–7 Myopic choroidal
neovascularization (mCNV) is a common vision-
threatening complication of pathologic myopia. Intra-
vitreal anti-vascular endothelial growth factor (VEGF)
has been shown to effectively improve and maintain
vision in patients with mCNV. The efﬁcacy and supe-
riority of ranibizumab in comparison with verteporﬁn
photodynamic therapy (vPDT) have been shown in the
RADIANCE trial and since 2014 anti-VEGF is
approved from Health Authorities for the treatment
of subfoveal mCNV.8,9
In addition to mCNV, intraretinal splitting of the
inner and outer retinal layers resulting in intraretinal
cystoid spaces is described in some myopic eyes. This
entity is recognized as myopic macular retinoschisis
(MRS) and may be best visualized with optical
coherence tomography (OCT).10,11 Myopic macular
retinoschisis is probably of degenerative nature and de-
velops spontaneously in eyes with pathologic myopia.
In the current study, the baseline OCT scans of both
eyes from all 277 patients included in the RADIANCE
trial have been reanalyzed for the presence of MRS and
it was explored if the presence of MRS affects the
visual and morphological outcome of patients with
mCNV treated with ranibizumab therapy for mCNV.
Methods
The design of the RADIANCE study has been
described in detail elsewhere.8 The key inclusion cri-
teria of the RADIANCE study were: 1) diagnosis
of active CNV secondary to pathologic myopia
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conﬁrmed by complete ocular examination; 2) pres-
ence of at least one of the following lesion types: a)
subfoveolar, b) juxtafoveolar with the involvement of
the central macular area, c) extrafoveolar with involve-
ment of the central macular area and d) margin of the
optic disk with involvement of the central macular
area; 3) BCVA$24 and#78 ETDRS letters at a start-
ing distance of 4 meters using ETDRS visual chart;
and 4) visual loss only because of the presence of any
eligible types of CNV related to pathological myopia
based on clinical ocular ﬁndings, ﬂuorescein angiog-
raphy, and OCT data.
Main exclusion criteria were: 1) history of stroke,
panretinal focal/grid laser photocoagulation with
involvement of the macular area, intraocular treatment
with corticosteroids and/or intraocular surgery within
3 months before randomization and treatment with
anti-VEGF or vPDT at any time in the study eye or
hypersensitivity to ranibizumab or verteporﬁn or to
drugs of similar class; 2) presence of CNV secondary
to any cause other than pathologic myopia.8
Brieﬂy, patients with visual impairment because of
myopic CNV were included and randomized to three
different treatment groups. Group 1 (n = 106) received
ranibizumab on Day 1, Month 1 and thereafter as
needed guided by visual acuity (VA) stabilization cri-
teria. Group 2 (n = 116) received ranibizumab on Day
1 and thereafter as needed guided by disease activity
criteria, and Group 3 (n = 55) was treated with vPDT
on Day 1 and from Month 3 disease activity was trea-
ted with ranibizumab and/or vPDT at investigators’
discretion (www.clinicaltrials.gov, NCT01217944).
In this study, a post hoc analysis of the patients
included in the RADIANCE trial (n = 277) was per-
formed to evaluate the impact of MRS on the functional
outcome in patients with mCNV undergoing intravitreal
(IVT) ranibizumab injections. Presence of MRS on OCT
scans was determined on the ﬁrst study visit. Epiretinal
membrane (ERM) and vitreoretinal traction (VMT) were
no exclusion criteria. Optical coherence tomography
cross-hair scans and volume scans performed either on
time domain or spectral domain OCT were analyzed by
two masked, independent graders of the Bern Photo-
graphic Reading Center (BPRC) and approved by a third
grader. Intraretinal splitting of the inner and outer retinal
layers resulting in intraretinal, hyporeﬂective cystoid
spaces on OCT was identiﬁed as MRS (Figure 1).10,11
Splitting within the outer plexiform layer and the outer
nuclear layer was recognized as outer MRS. Schisis cav-
ities found at the level of the inner plexiform, ganglion
cell layer, and retinal nerve ﬁber layer were deﬁned as
inner MRS.12,13 The inner nuclear layer deﬁned the neu-
roretinal boundary between inner and outer retinoschisis.
The presence of MRS in the fellow eyes and the devel-
opment of new MRS in both study and fellow eyes over
the 12-month period were evaluated as well to describe
the prevalence and incidence of MRS in this study pop-
ulation. Optical coherence tomography scans of the study
and fellow eyes were evaluated on a monthly basis.
Myopic choroidal neovascularization was diagnosed
using ﬂuorescein angiography, which was performed at
screening and at the end of the study. For the fellow
eyes, inclusion and exclusion criteria of the RADIANCE
study were applied with the only exception that mCNV
was not requested for the inclusion in the MRS study.
Localization of retinoschisis was determined using the
standard ETDRS grid on OCTs.
To evaluate the effect of MRS on the treatment
outcome of ranibizumab in mCNV, the study eyes of
the RADIANCE patients undergoing ranibizumab in-
jections were included in the post hoc visual function
analysis, whereas patients previously assigned to the
vPDT group were excluded. Best-corrected visual
acuity (BCVA) measured in Snellen visual acuity ratios
and mean change presented in ETDRS letters was
compared between baseline (BL) versus 3 and
12 months of treatment with IVT ranibizumab. Data
were analyzed using IBM Statistical software (SPSS 17;
IBM Inc, Chicago, IL). Statistical paired t-test was used
to compare the means. P-values#0.05 were considered
statistically signiﬁcant. Correlations were performed
using Pearson correlation coefﬁcient. Values are given
as mean ± SD. Prevalence and incidence of MRS were
obtained with descriptive statistics. The research fol-
lowed the tenets of the Declaration of Helsinki. Institu-
tional Review Board approval was granted.
Results
The RADIANCE study included 277 patients.
Optical coherence tomography scans were available
From the *Bern Photographic Reading Center, Department of
Ophthalmology, Inselspital, University Hospital, University of
Bern, Bern, Switzerland; †Department of Ophthalmology, Insel-
spital, University Hospital, University of Bern, Bern, Switzerland;
and ‡Novartis Pharma AG, Basel, Switzerland.
Supported by Novartis Pharma AG, Switzerland.
None of the authors have any ﬁnancial/conﬂicting interests to
disclose.
The sponsor participated in data management, review, and
approval of the manuscript.
This is an open access article distributed under the terms of the
Creative Commons Attribution-NonCommercial-NoDerivatives
License 4.0 (CC BY-NC-ND), which permits downloading and
sharing the work provided it is properly cited. The work cannot
be changed in any way or used commercially.
Reprint requests: Sebastian Wolf, MD, PhD, Department
of Ophthalmology, Inselspital, University Hospital, University
of Bern, Freiburgstrasse 10, Bern 3010, Switzerland; e-mail:
sebastian.wolf@insel.ch
2 RETINA, THE JOURNAL OF RETINAL AND VITREOUS DISEASES  2016  VOLUME 0  NUMBER 0
for all 277 study eyes and for 197 fellow eyes.
Therefore, a total of 474 eyes has been included into
this analysis and has been evaluated for the presence
and the development of MRS.
The prevalence of MRS was 6% in the RADIANCE
population. At BL visit, MRS was present in 6% (28/
474 of eyes) with pathologic myopia: 18 study eyes
and 10 fellow eyes showed respective alterations and
bilateral MRS were found in 4 of those 25 patients.
The incidence of MRS in the RADIANCE population
was 1.7% after 12 months, as 8 patients developed
new onset of this clinical feature (7 in the study eyes
and 1 in the fellow eye).
Demographic data and clinical characteristics of
patients with and without MRS are presented in
Table 1. Patients with MRS were generally older than
the patients without MRS (MRS (n = 25 patients): 62 ±
11 versus non-MRS (n = 252 patients): 55 ± 14 years;
P , 0.0001). Myopic macular retinoschisis was more
frequently found in woman (Table 1, P , 0.0001).
Mean central retinal thickness (CRT) did not
statistically signiﬁcantly differ between the MRS
group (452 ± 275 mm) and the non-MRS group
(359 ± 108 mm, P = 0.34). There was no correlation
between CRT and BCVA (Pearson correlation r =
0.10, P = 0.54).
All study eyes had mCNV, whereas only three of
the fellow eyes of the MRS group had mCNV at
baseline (Table 2). Otherwise, study and fellow eyes
with MRS showed no differences in terms of clinical
characteristics. Vitreomacular traction was present in
two study eyes with MRS but in none of the fellow
eyes with MRS. The majority of the eyes with MRS
had schisis in the outer retinal layers (15 study eyes
and 7 fellow eyes).
Myopic macular retinoschisis was most frequently
found (13/28 eyes [46%]) in the inner ETDRS sub-
ﬁelds. Details regarding the localization of MRS are
presented in Table 2. There was no correlation
between location of MRS and location of mCNV
(r = 0.24, P = 0.20), and there was also no correlation
between visual acuity and location of MRS (r = 0.075,
P = 0.66). During follow-up, new MRS developed in
1.7% (8/474) of high myopic eyes in the outer retinal
layers. None of them had vitreoretinal traction, but all
of respective eyes showed an ERM at BL. Two fellow
eyes with inner retinal schisis at baseline developed
outer schisis during follow-up. None of the patients
Fig. 1. Two different types of myopic macular retinoschisis: (A) example of outer retinoschisis; (B) example of inner retinoschisis; (C) example of both
inner and outer MRS.
Table 1. Comparison of Baseline Demographics Data of All RADIANCE Patients With and Without MRS Including Fellow
and Study Eyes
Non-MRS RADIANCE
(n = 252 Patients) MRS (n = 25 Patients) P




Axial length ± SD 29 ± 2 (26–31) 29 ± 2 (26–36) 0.076
Mean spherical equivalent ± SD
(min–max), D
212 ± 25 (26 to 230) 213 ± 26 (26 to 223) 0.57
BL VA ± SD (min–max), ETDRS
letters
61 ± 19 (10–88) 58 ± 20 (8–83) 0.35
Mean Snellen VA 20/120 20/130
CRT ± SD, mm 359 ± 108 452 ± 275 0.34
BL, baseline; CRT, central retinal thickness; ERM, epiretinal membrane; ETDRS, early treatment diabetic retinopathy study; MRS group,
patients who had initially MRS on study- or fellow eye; N, number of eyes; non-MRS, study eyes of patients with mCNV included in the
RADIANCE trial; SD, standard deviation; VA, visual acuity; VMT, vitreomacular traction.
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had progression of MRS to a macular hole or foveal
detachment during the follow-up period of 12 months.
No further changes in terms of MRS were registered
during the 12-month follow-up.
Baseline MRS was diagnosed in 18 study eyes.
Three of those eyes had been randomly assigned to
the vPDT treatment group and were therefore
excluded from our visual acuity outcome analysis.
Thus, a total of 15 eyes with MRS at BL were treated
with 0.5 mg of ranibizumab IVT for active mCNV
and were included in our evaluation. Patients’ BL
BCVA did not signiﬁcantly differ between the study
eyes with (n = 15) or without (n = 207) MRS treated
with ranibizumab: 57 ± 21 (mean Snellen visual
acuity 20/130) versus 56 ± 13 ETDRS letters (mean
Snellen visual acuity 20/150), respectively (P = 0.53).
At the 3 months, study eyes with MRS (n = 15) had
signiﬁcantly lower visual acuity gain compared to the
non-MRS study eyes (n = 207) treated with IVT
ranibizumab (2.8 ± 12.4 letters vs. 12.3 ± 9.4 letters
[P = 0.013] [Table 3]). After 12 months of follow-up,
both groups revealed signiﬁcant improvement in
visual acuity: 7.1 ± 14.5 versus 14.4 ± 10.5 (P =
0.16). Patients with MRS were treated more fre-
quently with IVT ranibizumab injections over the
12-month period: 5.8 ± 2.1 versus 4.0 ± 2.9 (P ,
0.0001). Most of the MRS patients treated with IVT
ranibizumab have been previously assigned to Group
2 (the “disease activity group”) (n = 13), whereas only
two MRS patients were treated based on the “visual
acuity stabilization criteria.”
Study eyes who developed newMRS over time (n = 7)
had a comparable visual acuity outcome after 12
months and received a similar number of injections
compared to study eyes with MRS at baseline. Two
eyes were treated according to the “disease activity”
treatment regimen, whereas the remaining mCNV eyes
with new onset MRS were treated according to the
“visual acuity stabilization” criteria.
Discussion
This is, to best of our knowledge, the biggest study
to evaluate the prevalence and functional outcome of
MRS in patients with mCNV. Further, it is so far the
biggest study to evaluate the treatment efﬁcacy of
ranibizumab in this respective patient population. The
prevalence and incidence of MRS was 6 and 1.7% in
our patient cohort, respectively. This is in line with
recently published manuscripts, which reported a prev-
alence ranging from 6.4 to 14.7%.7,14 Also, the spher-
ical equivalent and the axial length were very similar
between our study population and the recently
published data on patients with pathologic myopia
and MRS by Henaine-Berra et al7: 212.47 ± 4.99 D
versus 215.04 ± 5.33 D and 28.67 ± 1.87 mm versus
28.88 ± 2.31 mm, respectively. Our data also conﬁrm
Table 2. Characteristics of Study and Fellow Eyes With MRS at Baseline
Study Eye Fellow Eye




Mean spherical equivalent ± SD
(min–max), D
213 ± 26 (26 to 223) 212 ± 24 (26 to 18)
Type of MRS, n
VMT+outer schisis 2 0
Inner schisis 7 3
Outer schisis 15 7
ERM 16 8





BL VA ± SD (min–max) 59 ± 19 (33–78) 60 ± 21 (10–83)
Mean Snellen VA 20/130 20/125
MRS location, n
Central ETDRS subﬁeld 5 2
Inner ETDRS subﬁeld 9 4
Outer ETDRS subﬁeld 4 4
BL, baseline; ERM, epiretinal membrane; ETDRS, early treatment diabetic retinopathy study; N, number of eyes; VA, visual acuity; VMT,
vitreomacular traction.
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previous ﬁndings of Takano and Kishi15 which have
shown that MRS was more prevalent in older patients
with pathologic myopia.
The pathogenesis of MRS includes various mecha-
nisms.10–20 Degenerative aging processes within the
retina could lead to the development of MRS in eyes
with pathologic myopia.15,16 The weak adhesion
between the inner retina and the underlying sclera,
the mechanical dissociation attributable to the scleral
bowing, and the caving of the retina might facilitate
the development of the MRS in and around atrophic
areas.12,15–17
Vitreous traction and scleral and chorioretinal
changes are considered to be causative factors for
the formation of retinoschisis,12,15–19 whereas a dome-
shaped macula was deemed a protective factor pre-
venting MRS.16,17 Although vitreomacular traction
was only found in two of our cases with MRS, ERM
was found in the majority of our MRS cases. Thus,
tractional forces may have been a relevant factor for
the formation of MRS in our patient cohort. Another
possible explanation for MRS involves degenerative
processes of the staphylomatous region in myopic
eyes.15 Optical coherence tomography images of pos-
terior outer retinoschisis in high myopia resemble the
histological appearance of typical peripheral microcys-
toid degeneration. In general, this peripheral cystoid
degeneration shows retinal splitting of the outer plex-
iform layer.16,20 Consistently, most eyes in our study
had schisis in the outer retinal layers and two eyes with
initial inner retinal schisis developed outer retinal schi-
sis over time.
Although we identiﬁed eight eyes with new onset
MRS over the period of 12 months, we did not notice
the development of full thickness macular holes or
subretinal detachments. The only progressive changes
were found in two fellow eyes, which developed outer
retinal schisis in preexisting inner MRS. Previous
studies reported progression of MRS to full thickness
macular holes or foveal detachment and spontaneous
improvement, but the majority of the affected eyes
were reported to remain stable.11,16,18,21 The lack of
progression to full-thickness macular holes in our study
in comparison with previously published studies may
have been due to the fact that our observational period
was only 12 months. Signiﬁcant progression of MRS
may manifest after a longer follow-up period and the
observational period may have been too short to detect
the changes. However, a previous study reported full-
thickness macular hole formation within a mean
follow-up period of 15 months.22 Another explanation
may be found in a possible interaction between mCNV,
continuous anti-VEGF treatment, and MRS.
Intravitreal anti-VEGF injections have been pre-
viously discussed as a potential risk factor for pro-
gression of MRS in myopic eyes with CNV. Huang
et al21 identiﬁed aggravation of MRS and an increase
of central retinal thickness under ranibizumab treat-
ment in 81 of 83 mCNV patients with preexisting
ERM and MRS. Lai et al23 reported development of
macular hole (1/37 eyes) and worsening of MRS (2/37
eyes) after intravitreal injections for mCNV. The au-
thors concluded that respective complications might or
might not be related to the application of intravitreal
injections.23 Our patient cohort presented new devel-
opment of outer MRS in preexisting inner MRS in two
fellow eyes, whereas new MRS developed in seven
treated, study eyes but only in one, untreated fellow
eye. Thus, the higher incidence of new onset MRS in
the study eyes may be related to the administration of
ranibizumab. None of our study eyes showed MRS
aggravation and although their treatment response
was rather delayed and a higher number of IVTs were
needed compared with the non-MRS mCNV patients,
study eyes showed signiﬁcant and comparable visual
function improvement under continuous ranibizumab
administration after 12 months. This ﬁnding in turn
rather suggests a beneﬁcial than a worsening effect
Table 3. Comparison of Visual Outcomes of Eyes With and Without Macular Retinoschisis (MRS) Treated With Intravitreal
Ranibizumab for Myopic Choroidal Neovascularization
Non-MRS Study







P (Non-MRS vs. MRS
Study Eyes)
BL VA, ETDRS letters 56 ± 13 57 ± 21 0.53
Mean Snellen VA 20/150 20/130
3 months VA gain,
ETDRS letters
12.30 ± 9.4 0.0001 2.8 ± 12.4 0.009 0.013
12 months VA gain,
ETDRS letters
14.4 ± 10.5 0.0001 7.1 ± 14.5 0.025 0.16
Number of IVT
injections
4.0 ± 2.9 5.8 ± 2.1 ,0.0001
BL, baseline; ERM, epiretinal membrane; ETDRS, early treatment diabetic retinopathy study; IVT, intravitreal; N, number of eyes;
VA, visual acuity; VMT, vitreomacular traction.
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of continuous ranibizumab treatment in this patient
cohort. Nevertheless, numerically more study eyes
than fellow eyes developed new onset MRS.
Furthermore, the mechanical procedure of injection
may inﬂuence the vitreomacular interface and may
therefore be a contributing factor for the development
of MRS in eyes with mCNV, given that the adhesion
and traction of the vitreous on the posterior pole can
cause MRS and myopic traction maculopathy.18,24 The
injection procedure may induce posterior vitreous
detachment in patients with CNV although this is very
rare unless there is focal vitreomacular adhesion.24
Another inﬂuencing mechanism might be the shrink-
age of the ﬁbrovascular tissue induced by anti-VEGF
agents. This contraction might lead to tractional forces
and enhance to some degree the separation of the neu-
ral retina, which could lead to the onset of MRS.
Myopic macular retinoschisis was most frequently
found in the inner ETDRS subﬁeld. There was no
correlation between BCVA and location of MRS,
which may be best explained by the fact that the
presence of mCNV may have a stronger impact on
BCVA than MRS.
In our study, almost all the eyes (16/18) with MRS
had an ERM at BL. The MRS study eyes received
signiﬁcantly more intravitreal ranibizumab injection
when compared with the non-MRS eyes (5.8 ± 2.1 vs.
4.0 ± 2.9, P , 0.0001). These facts together with the
ﬁnding of Huang et al21 that eyes with MRS aggrava-
tion presented an ERM, are highly indicative that
ERM is an independent key factor for MRS formation
and aggravation. The high prevalence of ERM (89%)
in this group may be also causative for the higher
treatment need and deferred treatment response in pa-
tients with MRS and mCNV. Distribution and pene-
tration of ranibizumab into and throughout
retinochoroidal layers may differ in eyes with respec-
tive alterations. Further, the tractional force to the ret-
ina, leading to interstitial tissue pressure decrease,
results in an inﬂux of ﬂuid from the blood vessels
and contributes to intraretinal ﬂuid evident in neovas-
cular age-related macular degeneration.25 Similar
mechanisms have been described in vitreoretinal trac-
tion.26 Cuilla et al27 found that neovascular AMD pa-
tients with vitreomacular adhesion and vitreomacular
traction needed signiﬁcantly more intravitreal injec-
tions over two years than patients without vitreomac-
ular interface alterations.
A potential limitation of this study may be the use of
last generation, low-resolution time-domain-OCT
(TD-OCT, Stratus): 30% patients of the RADIANCE
study and 8% of our MRS group were followed with
TD-OCT. However, previous studies did not ﬁnd
a signiﬁcant difference in the ability of SD-OCT to
detect vitreomacular adhesion and vitreoretinal traction
when compared with TD-OCT.27,28 In addition, all im-
ages were carefully analyzed by three independent
graders, both facts that should limit the potential bias.
To summarize, MRS is a progressive, degenerative
alteration in pathologic myopia and may be found in
conjunction with mCNV. Frequent and continuous
anti-VEGF treatment effectively control mCNV in
eyes with MRS and lead to satisfying treatment
results. More intravitreal injections may be needed
in these cases to achieve comparable results. Intra-
vitreal interventions may affect the development but
rather not the course of existing MRS in high myopic
eyes. However, we should be cautious in concluding
that there is no signiﬁcant difference in visual out-
come and morphological response in mCNV patients
with or without MRS based on our relatively low
number of patients. Further studies and observations
with larger number of patients and longer term of
follow-up are needed.
Key words: pathologic myopia, macular retinoschi-
sis, choroidal neovascularization, ranibizumab.
References
1. Williams KM, Bertelsen G, Cumberland P, et al. Increasing
prevalence of myopia in Europe and the impact of education.
Ophthalmology 2015;122:1489–1497.
2. Vitale S, Sperduto RD, Ferris FL III. Increased prevalence of
myopia in the United States between 1971–1972 and 1999–
2004. Arch Ophthalmol 2009;127:1632–1639.
3. Parssinen O. The increased prevalence of myopia in Finland.
Acta Ophthalmol 2012;90:497–502.
4. Pan CW, Ramamurthy D, Saw SM. Worldwide prevalence and
risk factors for myopia. Ophthalmic Physiol Opt 2012;32:3–16.
5. Neelam K, Cheung CM, Ohno-Matsui K, et al. Choroidal neo-
vascularization in pathological myopia. Prog Retin Eye Res
2012;31:495–525.
6. Lin LL, Shih YF, Hsiao CK, Chen CJ. Prevalence of myopia in
Taiwanese school-children: 1983 to 2000. Ann Acad Med
Singapore 2004;33:27–33.
7. Henaine-Berra A, Zand-Hadas IM, Fromow-Guerra J, Garcia-
Aguirre G. Prevalence of macular anatomic abnormalities in
high myopia. Ophthalmic Surg Lasers Imaging Retina 2013;
44:140–144.
8. Wolf S, Balciuniene VJ, Laganovska G, et al. RADIANCE:
a randomized controlled study of ranibizumab in patients with
choroidal neovascularization secondary to pathologic myopia.
Ophthalmology 2014;121:682–692.e682.
9. Ikuno Y, Ohno-Matsui K, Wong TY, et al. Intravitreal aﬂi-
bercept injection in patients with myopic choroidal neovascu-
larization: the MYRROR study. Ophthalmology 2015;122:
1220–1227.
10. Jiang C, Wang W, Xu G, Wang L. Retinoschisis at macular
area in highly myopic eye by optic coherence tomography.
Yan Ke Xue Bao 2006;22:190–194.
11. Shimada N, Ohno-Matsui K, Baba T, et al. Natural course of
macular retinoschisis in highly myopic eyes without macular
hole or retinal detachment. Am J Ophthalmol 2006;142:
497–500.
6 RETINA, THE JOURNAL OF RETINAL AND VITREOUS DISEASES  2016  VOLUME 0  NUMBER 0
12. Fujimoto M, Hangai M, Suda K, Yoshimura N. Features asso-
ciated with foveal retinal detachment in myopic macular reti-
noschisis. Am J Ophthalmol 2010;150:863–870.
13. Sayanagi K, Ikuno Y, Tano Y. Tractional internal limiting
membrane detachment in highly myopic eyes. Am J Ophthal-
mol 2006;142:850–852.
14. Kamal-Salah R, Morillo-Sanchez MJ, Rius-Diaz F, Garcia-
Campos JM. Relationship between paravascular abnormalities
and foveoschisis in highly myopic patients. Eye (Lond) 2015;
29:280–285.
15. Takano M, Kishi S. Foveal retinoschisis and retinal detachment
in severely myopic eyes with posterior staphyloma. Am J Oph-
thalmol 1999;128:472–476.
16. Benhamou N, Massin P, Haouchine B, et al. Macular retinoschisis
in highly myopic eyes. Am J Ophthalmol 2002;133:794–800.
17. Garcia-Ben A, Blanco MJ, Pineiro A, et al. Relationship
between macular bending and foveoschisis in myopic patients.
Optom Vis Sci 2014;91:497–506.
18. Shimada N, Tanaka Y, Tokoro T, Ohno-Matsui K. Natural course
of myopic traction maculopathy and factors associated with pro-
gression or resolution. Am J Ophthalmol 2013;156:948–957.e941.
19. Ikuno Y, Sayanagi K, Ohji M, et al. Vitrectomy and internal
limiting membrane peeling for myopic foveoschisis. Am J
Ophthalmol 2004;137:719–724.
20. Paulus YM, Bressler NM. Spontaneous improvement in myo-
pic foveoschisis. Eye (Lond) 2014;28:1519–1520.
21. Huang J, Chen T, Lu Y, et al. Retinoschisis and intravitreal
ranibizumab treatment for myopic choroidal neovasculariza-
tion. Chin Med J (Engl) 2014;127:2053–2057.
22. Rey A, Jurgens I, Maseras X, Carbajal M. Natural course and
surgical management of high myopic foveoschisis. Ophthal-
mologica 2014;231:45–50.
23. Lai TY, Luk FO, Lee GK, Lam DS. Long-term outcome of
intravitreal anti-vascular endothelial growth factor therapy with
bevacizumab or ranibizumab as primary treatment for subfo-
veal myopic choroidal neovascularization. Eye (Lond) 2012;
26:1004–1011.
24. Veloso CE, Kanadani TM, Pereira FB, Negemy MB. Vitreo-
macular interface after anti-vascular endothelial growth factor
injections in neovascular age- related macular degeneration.
Ophthalmology 2015;122:1569–1572.
25. Kang EC, Koh HJ. Effects of vitreomacular adhesion on age-
related macular degeneration. J Ophthalmol 2015:865083. doi:
10.1155/2015/865083. Epub ahead of print.
26. Kaiser PK, Riemann CD, Sears JE, Lewis H. Macular trac-
tion detachment and diabetic macular edema associated with
posterior hyaloidal traction. Am J Ophthalmol 2001;131:
44–49.
27. Cuilla TA, Ying G, Maguire MG, et al. Inﬂuence of the vitre-
omacular interface on treatment outcomes in the comparison of
age-related macular degeneration treatments trials. Ophthal-
mology 2015;122:1203–1211.
28. Folgar FA, Jaffe GJ, Ying GS, Maguire MG, Toth CA; Com-
parison of Age-Related Macular Degeneration Treatments
Trials Research Group. Comparison of optical coherence
tomography assessments in the comparison of age-related
macular degeneration treatments trials. Ophthalmology 2014;
121:1956–1965.
MACULAR RETINOSCHISIS IN PATHOLOGIC MYOPIA  CEKLIC ET AL 7
